Artal Group’s Stoke Therapeutics STOK Stock Holding History

Artal Group’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-300,000	Closed	-$4.05M	–	128
2024 Q1	$4.05M	Buy	+300,000	New	+$1.82M	0.1%	69
2023 Q3	–	Sell	-250,000	Closed	-$2.66M	–	118
2023 Q2	$2.66M	Hold	250,000	–	–	0.08%	79
2023 Q1	$2.08M	Hold	250,000	–	–	0.12%	80
2022 Q4	$2.31M	Hold	250,000	–	–	0.13%	85
2022 Q3	$3.21M	Hold	250,000	–	–	0.14%	76
2022 Q2	$3.3M	Hold	250,000	–	–	0.18%	77
2022 Q1	$5.26M	Hold	250,000	–	–	0.22%	75
2021 Q4	$6M	Hold	250,000	–	–	0.16%	95
2021 Q3	$6.36M	Hold	250,000	–	–	0.14%	104
2021 Q2	$8.41M	Hold	250,000	–	–	0.17%	96
2021 Q1	$9.71M	Hold	250,000	–	–	0.17%	101
2020 Q4	$15.5M	Sell	250,000 -20,750	-8%	-$951K	0.33%	69
2020 Q3	$9.07M	Sell	270,750 -14,250	-5%	-$407K	0.22%	80
2020 Q2	$6.79M	Buy	285,000 +35,000	+14%	+$831K	0.19%	89
2020 Q1	$5.72M	Buy	+250,000	New	+$6.18M	0.24%	71

Other funds holding STOK

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group's STOK Position: Q2 2024 in Review

Artal Group sold out of Stoke Therapeutics (STOK) in Q2 2024, closing a stake of 300,000 shares — an estimated $4.05M sold.

Artal Group first reported a position in STOK in Q1 2020 and held it in 15 quarters. The position peaked at $15.5M in Q4 2020. 114 funds tracked by Wall St. Rank hold STOK as of Q2 2024.

Artal Group reported no remaining Stoke Therapeutics position as of Q2 2024 after selling out during the quarter.
Artal Group sold 300,000 Stoke Therapeutics shares in Q2 2024, an estimated $4.05M.
Artal Group first reported a position in Stoke Therapeutics in Q1 2020 and held it in 15 quarters.
Artal Group's Stoke Therapeutics position peaked at $15.5M in Q4 2020.
114 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2024.

Based on Artal Group's 13F filing for Q2 2024, filed 14 Aug 2024.